questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines du cytosquelette
Protéines de filaments intermédiaires
Protéines de filaments intermédiaires : Questions médicales fréquentes
Termes MeSH sélectionnés :
Quantitative Structure-Activity Relationship
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines de filaments intermédiaires : Questions médicales les plus fréquentes",
"headline": "Protéines de filaments intermédiaires : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines de filaments intermédiaires : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-03",
"dateModified": "2025-02-28",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines de filaments intermédiaires"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines du cytosquelette",
"url": "https://questionsmedicales.fr/mesh/D003598",
"about": {
"@type": "MedicalCondition",
"name": "Protéines du cytosquelette",
"code": {
"@type": "MedicalCode",
"code": "D003598",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.220"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Desmine",
"alternateName": "Desmin",
"url": "https://questionsmedicales.fr/mesh/D003893",
"about": {
"@type": "MedicalCondition",
"name": "Desmine",
"code": {
"@type": "MedicalCode",
"code": "D003893",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.220.475.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine gliofibrillaire acide",
"alternateName": "Glial Fibrillary Acidic Protein",
"url": "https://questionsmedicales.fr/mesh/D005904",
"about": {
"@type": "MedicalCondition",
"name": "Protéine gliofibrillaire acide",
"code": {
"@type": "MedicalCode",
"code": "D005904",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.220.475.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Kératine-15",
"alternateName": "Keratin-15",
"url": "https://questionsmedicales.fr/mesh/D053569",
"about": {
"@type": "MedicalCondition",
"name": "Kératine-15",
"code": {
"@type": "MedicalCode",
"code": "D053569",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.220.475.450.300.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Vimentine",
"alternateName": "Vimentin",
"url": "https://questionsmedicales.fr/mesh/D014746",
"about": {
"@type": "MedicalCondition",
"name": "Vimentine",
"code": {
"@type": "MedicalCode",
"code": "D014746",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.220.475.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protéines de filaments intermédiaires",
"alternateName": "Intermediate Filament Proteins",
"code": {
"@type": "MedicalCode",
"code": "D007381",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sarah Köster",
"url": "https://questionsmedicales.fr/author/Sarah%20K%C3%B6ster",
"affiliation": {
"@type": "Organization",
"name": "Institute for X-Ray Physics, University of Goettingen, Friedrich-Hund-Platz 1, 37077 Göttingen, Germany."
}
},
{
"@type": "Person",
"name": "Sandrine Etienne-Manneville",
"url": "https://questionsmedicales.fr/author/Sandrine%20Etienne-Manneville",
"affiliation": {
"@type": "Organization",
"name": "Cell Polarity, Migration and Cancer Unit, Institut Pasteur, UMR3691 CNRS, Équipe Labellisée Ligue Contre le Cancer, F-75015 Paris, France. Electronic address: setienne@pasteur.fr."
}
},
{
"@type": "Person",
"name": "Charlotta Lorenz",
"url": "https://questionsmedicales.fr/author/Charlotta%20Lorenz",
"affiliation": {
"@type": "Organization",
"name": "Institute for X-Ray Physics, University of Göttingen, Friedrich-Hund-Platz 1, 37077 Göttingen, Germany."
}
},
{
"@type": "Person",
"name": "Anna V Schepers",
"url": "https://questionsmedicales.fr/author/Anna%20V%20Schepers",
"affiliation": {
"@type": "Organization",
"name": "Institute for X-Ray Physics, University of Göttingen, Friedrich-Hund-Platz 1, 37077 Göttingen, Germany."
}
},
{
"@type": "Person",
"name": "Rudolf E Leube",
"url": "https://questionsmedicales.fr/author/Rudolf%20E%20Leube",
"affiliation": {
"@type": "Organization",
"name": "Institute of Molecular and Cellular Anatomy, RWTH Aachen University, Aachen, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Quantitative Structure Retention-Relationship Modeling: Towards an Innovative General-Purpose Strategy.",
"datePublished": "2023-02-10",
"url": "https://questionsmedicales.fr/article/36838689",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules28041696"
}
},
{
"@type": "ScholarlyArticle",
"name": "Predictive Quantitative Read-Across Structure-Property Relationship Modeling of the Retention Time (Log",
"datePublished": "2023-06-09",
"url": "https://questionsmedicales.fr/article/37294004",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1021/acs.jafc.3c01438"
}
},
{
"@type": "ScholarlyArticle",
"name": "Modeling of Anticancer Sulfonamide Derivatives Lipophilicity by Chemometric and Quantitative Structure-Retention Relationships Approaches.",
"datePublished": "2022-06-21",
"url": "https://questionsmedicales.fr/article/35807212",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/molecules27133965"
}
},
{
"@type": "ScholarlyArticle",
"name": "Exploring structure-activity relationships for polymer biodegradability by microorganisms.",
"datePublished": "2023-05-19",
"url": "https://questionsmedicales.fr/article/37211122",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.scitotenv.2023.164338"
}
},
{
"@type": "ScholarlyArticle",
"name": "Exploring quantitative structure-property relationship models for environmental fate assessment of petroleum hydrocarbons.",
"datePublished": "2022-11-10",
"url": "https://questionsmedicales.fr/article/36355241",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11356-022-23904-x"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines du cytosquelette",
"item": "https://questionsmedicales.fr/mesh/D003598"
},
{
"@type": "ListItem",
"position": 5,
"name": "Protéines de filaments intermédiaires",
"item": "https://questionsmedicales.fr/mesh/D007381"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines de filaments intermédiaires - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines de filaments intermédiaires",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Général",
"headline": "Général sur Protéines de filaments intermédiaires",
"description": "Erreur lors de la génération.",
"url": "https://questionsmedicales.fr/mesh/D007381?mesh_terms=Quantitative+Structure-Activity+Relationship&page=4#section-général"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Erreur lors de la génération.",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Veuillez réessayer ultérieurement."
}
}
]
}
]
}
Reversed-Phase Liquid Chromatography (RPLC) is a common liquid chromatographic mode used for the control of pharmaceutical compounds during their drug life cycle. Nevertheless, determining the optimal...
The retention time (log...
Sulfonamides are a classic group of chemotherapeutic drugs with a broad spectrum of pharmacological action, including anticancer activity. In this work, reversed-phase high-performance liquid chromato...
Research on the environmental biodegradation or microbial biodegradation of polymers has substantially increased recently due to growing demand for biodegradable polymers for certain applications. Env...
The rate and extent of biodegradation of petroleum hydrocarbons in the different aquatic environments is an important element to address. The major avenue for removing petroleum hydrocarbons from the ...
Antibiotics are often found in the environment as pollutants. They are usually found as mixtures in the environment and may produce toxicity against different ecological species due to joint exposure ...
The current effort towards the digital transformation across multiple scientific domains requires data that is Findable, Accessible, Interoperable and Reusable (FAIR). In addition to the FAIR data, wh...
To address this challenge, we utilized 34 datasets from the nanosafety domain by exploiting the NanoSafety Data Reusability Assessment (NSDRA) framework, which allowed the annotation and assessment of...
Universal regression and classification QSARs reached an 0.86 R...
This study reveals that the digitalization of nanosafety knowledge in a reproducible manner has a long way towards its successful pragmatic implementation. The workflow carried out in the study shows ...
Heterogeneous peroxymonosulfate (PMS) treatment is recognized as an effective advanced oxidation process (AOP) for the treatment of organic contaminants. Quantitative structure-activity relationship (...
Liquid crystal materials (LCMs) are considered as emerging contaminants with high persistent and bioaccumulative potentials, but their toxicological effects are not well understood. To address this is...
The present study identifies and analyses the degraded products of three azo dyes (Reactive Orange 16, Reactive Red 120, and Direct Red 80) and proffers their in silico toxicity predictions. In our pr...
